Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The Medicines Company (MDCO - Analyst Report) reported first quarter earnings of 24 cents per share, compared with the year-ago earnings of 14 cents per share.

Including one-time items, the company reported a loss of 21 cents per share compared to the year-ago earnings of 14 cents per share. The Zacks Consensus Estimate for the first quarter of 2013 was a loss of 27 cents. First quarter 2013 revenues increased 23% year over year to $155.8 million, in line with the Zacks Consensus Estimate.

The Quarter in Detail

Angiomax US sales increased 14% to $131.3 million. Ex-US sales of Angiomax increased 9% to $11.6 million during the quarter. The Medicines Company reported an increase in market share in the low risk percutaneous coronary intervention (PCI) segment in the US. We note that the company took a price increase of 7% for Angiomax in January.

Recothrom sales in the US were $8.6 million. The Medicines Company started selling Recothrom from Feb 8, 2013 under its collaboration with Bristol-Myers Squibb (BMY - Analyst Report).

Adjusted research and development expenses during the quarter decreased 2.2% to $32.1 million.

Adjusted selling, general and administrative expenses increased 28.4% to $55.5 million for the quarter.

2013 Guidance

The Medicines Company remains on track to achieve net revenue growth of 20%−22% in 2013. The Medicines Company intends to seek marketing approval for Cangrelor in the US in the second quarter of 2013 and in the EU by year end. The company will seek approval for Cangrelor for all PCIs in all patient subgroups and in patients who require bridging from oral antiplatelet therapy before surgery.

Meanwhile, results on oritavancin from the SOLO-II study should be out by mid-2013. Positive results from the SOLO-I study were presented in Dec 2012. Oritavancin is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible grampositive bacteria, including methicillin-resistant staphylococcus aureus (MRSA).

However, the delay in Medicines Company’s plans for filing for US approval of Ionsys is disappointing. Ionsys is a compact, disposable, needleless patient-controlled analgesia (PCA) system which is being developed for the short-term management of acute postoperative pain in the hospital setting.

The Medicines Company said that it is upgrading the integrated electronics and software prior to filing so as to improve the reliability and safety of the device. As a result, the company now expects to file for approval in the US in early 2014 instead of late 2013. The EU marketing application will be filed shortly after the filing of the US application.

The Medicines Company currently carries a Zacks Rank #2 (Buy). We expect Angiomax to continue performing well. Moreover, we are pleased to see management actively pursuing in-licensing deals and acquisitions to drive growth.

Companies that currently look well-positioned include Athersys, Inc. (ATHX - Snapshot Report) and Cleveland BioLabs, Inc. (CBLI - Snapshot Report). Both are Zacks Rank #1 (Strong Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%